Potentiation of the antitumor activity by a novel quinoline compound, ms-209, in multidrug-resistant solid tumor cell lines

Oncology Research

Volumn 9, Issue 2, 1997, Pages 61-69

  Nakanishi, Osamu ^a   Baba, Makoto ^b   Saito, Akiko ^c   Yamashita, Takashi ^d   Sato, Wakao ^d   Abe, Hayao ^b   Fukazawa, Nobuyuki ^c   Suzuki, Tsuneji ^d   Sato, Shigeo ^b   Naito, Mikihiko ^d   Tsuruoj, Takashi ^c  

^a Mitsui Pharmaceuticals Inc ^*  (Japan)

^b MITSUI CHEMICALS INC   (Japan)

^c CANCER INSTITUTE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adriamycin; MS 209; Multidrug resistance; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; DOFEQUIDAR; DOXORUBICIN; QUINOLINE DERIVATIVE; VINCRISTINE;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL DIVISION; COLON TUMOR; COLORECTAL TUMOR; DBA MOUSE; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL MELANOMA; FEMALE; HUMAN; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, NUDE; QUINOLINES; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0030629467     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Endicott, J. A.; Ling, V. The biochemistry of p-glycoproteinmediated multidrug resistance. Annu. Rev. Biochem. 58:137-171; 1989.
2. Hamada, H.; Tsuruo, T. Functional role for the 170- to 180kDa glycoprotein specific to drug resistant tumor cells as revealed by monoclonal antibodies. Proc. Nail. Acad. Sci. USA 89:7785-7789; 1986.
3. Moscow, J. A.; Cowan, K. H. Multidrug resistance. J. Natl. Cancer Inst. 80:14-20; 1988.
4. Naito, M.; Hamada, H.; Tsuruo, T. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug resistant K562 cells. J. Biol. Chem. 263:11887-11891; 1988.
5. Tsuruo, T. Mechanism of multidrug resistance and implications of therapy. Jpn. J. Cancer Res. 79:285-296; 1988.
6. Tsuruo, T.; lida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972; 1981.
7. Tsuruo, T.; lida, H.; Tsukagoshi, S.; Sakurai, Y. Increased accumulation of vincristine and adriamycin in drug-resistant tumor cells following incubation with calcium antagonist and calmodulin inhibitors. Cancer Res. 42:4730-4733; 1982.
8. Tsuruo, T.; lida, H.; Nojiri, M.; Tsukagoshi, S.; Sakurai, Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 43: 2905-2910; 1982.
9. Tsuruo, T.; lida, H.; Kikatani, Y.; Yokota, K.; Tsukagoshi, S.; Sakurai, Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 44: 4303-4307; 1984.
10. Tsuruo, T.; Saito, H. I.; Kawabata, H.; Oh-hara, T.; Hamada, H.; Utakoji, T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn. J. Cancer Res. 77: 682-692; 1986.
11. Yusa, K.; Tsuruo, T. Reversal mechanism of multidrug resis-tance by verapamil: Direct binding of verapamil to Pglycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49:5002-5006; 1989.
12. Naito, M.; Hamada, H.; Tsuruo, T. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrugresistant K562 cells. J. Biol. Chem. 263:11887-11891; 1988.
13. Naito, M.; Tsuruo, T. Compétitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug resistant K562 cells without calcium ion involvement. Cancer Res. 49:1452-1455; 1989.
14. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199; 1990.
15. Slater, L. M.; Sweet, P.; Stupeckey, M.; Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77: 1405-1408; 1986.
16. Boesch, D.; Muller, K.; Manzanedo, A. P.; Loor, F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell. Res. 196: 26-32;1991.
17. Naito, M.; Oh-hara, T.; Yamazaki, A.; Danki, T.; Tsuruo, T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol. 29:195-200; 1992.
18. Bessho, F.; Kinumaki, H.; Kobayashi, M.; Habu, H.; Nakamura, K.; Yokota, S.; Tsuruo, T.; Kobayashi, M. Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med. Pediatr. Oncol. 13:199-202; 1985.
19. Dalton, W. S.; Grogan, T. M.; Meltzer, P. S.; Scheper, R. L.; Durie, B. G. M.; Taylor, C. W.; Miller, T. P.; Salmon, S. E. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7:415-424; 1989.
20. Kerr, D. J.; Graham, J.; Cummings, J.; Morrison, J. G.; Thompson. G. G.; Brodie, M. J.; Kaye, S. B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Phamacol. 18:239-242; 1986.
21. Presant, C. A.; Kennedy, P. S.; Wiseman, C.; Gala, K.; Bouzaglou, A.; Wyrcs, M.; Naessig, V. Verapamil reversal of clinical doxorubicin resistance in human cancer: Wilshire Oncology Medical Group pilot phase I-II study. Am. J. Clin. Oncol. 9:355-357; 1986.
22. Miller, R. L.; Bukowski, R. M.; Budd, G. T.; Purvis, J.; Weick, J. K.; Shepard, K.; Midha, K. K.; Ganapathi, R. Clinical modulation of doxorubicin resistance by the calmodulininhibitor, Trifluoperazine: A phase I/II trial. J. Clin. Oncol. 6:880-888; 1988.
23. Sato, W.; Fukazawa, N.; Suzuki, T.; Yusa, K.; Tsuruo, T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res. 51:2420-2424; 1991.
24. Sato, W.; Fukazawa, N.; Nakanishi, O.; Baba, M.; Suzuki, T.; Yano, O.; Naito, M.; Tsuruo, T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother. Pharmacol. 35:271-277; 1995.
25. Fukazawa, N.; Odate, M.; Suzuki, T.; Otsuka, K.; Sato, W.; Tsuruo, T. Novel heterocyclic compounds and anticancerdrug reinforcing agents containing them as effective components. European Patent 0363212, European Patent Office, Munich; 1989.
26. Rogan, A. M.; Hamilton, T. C.; Young, R. C.; Klecker, R. W., Jr.; Ozols, R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224:994-996; 1984.
27. Akiyama, S.; Fojo, A.; Hanover, J. A.; Pastan, I.; Gottesman, M. M. Isolation and characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet. 11: 117-126:1985.
28. Carmichael, J. D.; Degraff, W. G.; Gazder, A. F.; Minna, J. D.; Michell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47:936-942; 1987.
29. Baba, M.; Nakanishi, O.; Saito, A.; Miyama, Y.; Yano, O.; Shimada, S.; Fukazawa, N.; Naito, M.; Tsuruo, T. Relationship between the multidrug resistant gene expression and multidrug resistance reversing activity of MS-209 in various tumor cells. Cancer Chemother. Pharmacol. 36:361-367; 1995.